Biosimilar Pipeline (e.g., Bevacizumab, Trastuzumab)
Oncology, Autoimmune Diseases
Key Facts
Indication
Oncology, Autoimmune Diseases
Phase
Phase 3 / Registration
Status
Active
Company
About Zydus Lifesciences
Zydus Lifesciences is a mission-driven global pharmaceutical company dedicated to creating healthier, happier communities worldwide. Its strategy is built on a dual engine of deep expertise in complex generics and a robust innovation pipeline in novel chemical entities (NCEs), biologics, and vaccines. Key achievements include launching Lipaglyn, the first NCE from an Indian research pipeline, and pioneering biosimilars like Exemptia (adalimumab), while maintaining strong financial growth and a vast commercial footprint.
View full company profileTherapeutic Areas
Other Oncology, Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Portfolio (e.g., rituximab, bevacizumab) | R-Pharm | Phase 3 / Registration |